IP Library › Granted Patent US 10,793,567
Granted Patent B2
US 10,793,567 · App. 16/477,466 · Granted Oct 6, 2020

Bicyclic inhibitors of histone deacetylase

Inventors: Nathan Oliver Fuller (Arlington, MA); John A. Lowe, III (Stonington, CT)
Assignee: Rodin Therapeutics, Inc.
C07D471/04A61K31/437A61K31/519A61P25/28C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,567
App. No.
16/477,466
Granted
Oct 6, 2020
Kind
B2
Abstract

Provided are compounds of the formula and pharmaceutically acceptable salts and composition thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g. HDAC2).

Claims (30)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein the compound is of the Formula:

or a pharmaceutically acceptable salt thereof.

15. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

16. A method of inhibiting HDAC activity in a subject comprising the step of administering to the subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, or the composition of claim 15 .

Assignments (5)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073790/0950 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (072656/0509) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES, INC.
Reel/Frame 074858/0481 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 072656/0509 →
CHANGE OF NAME Recorded Dec 1, 2020
From: RODIN THERAPEUTICS, INC.
To: ALKERMES, INC.
Reel/Frame 054504/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: FULLER, NATHAN OLIVER; LOWE, JOHN A., III
To: RODIN THERAPEUTICS, INC.
Reel/Frame 050046/0988 →